22 Spam-Free Article(s) Found
Sort:
Relevance
Like
Date
Filter:
7d
All
DeepLinks
Article Searches
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program https://www.zacks.com/stock/news/2223497/jazz-boosts-oncology-pipeline-with-kras-inhibitor-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2223497 Feb 08, 2024 - JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414 Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks? https://www.fool.com/investing/2024/02/17/is-it-too-late-to-buy-these-2-brilliant-passive-in/?source=iedfolrf0000001 Feb 17, 2024 - Patience will be rewarded with these stocks.
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts https://www.zacks.com/stock/news/2237621/bristol-myers-squibb-bmy-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2237621 Mar 07, 2024 - In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242244 Mar 18, 2024 - Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B https://www.zacks.com/stock/news/2243580/astrazeneca-azn-to-buy-fusion-pharmaceuticals-for-2-4b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243580 Mar 20, 2024 - AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts https://www.zacks.com/stock/news/2246994/bristol-myers-squibb-bmy-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2246994 Mar 27, 2024 - In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839 Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors https://www.zacks.com/stock/news/2255656/bristol-myers-squibb-bmy-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2255656 Apr 15, 2024 - Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.

Pages: 123

Page 1>